Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

GCC 0901- A Phase II Study of Letrozole in Combination With Lapatinib Followed by an Addition of Everolimus in Postmenopausal Women With Advanced Endocrine Resistant Breast Cancer

NCT01499160 is registered in ClinicalTrials.gov with University of Maryland, Baltimore as lead sponsor.

NCT NCT01499160
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01499160 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
GCC 0901- A Phase II Study of Letrozole in Combination With Lapatinib Followed by an Addition of Everolimus in Postmenopausal Women With Advanced Endocrine Resistant Breast Cancer
Lead sponsor
University of Maryland, Baltimore
Phase
Phase 2
Overall status
Terminated
Start date
May 31, 2012
Completion date
December 31, 2016
Enrollment
7 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast neoplasms, endocrine breast diseases, neoplasm metastasis